15/08/2025
6 Series | 60 Seconds with…
Did you know that 35% of our current research trials are commercially funded?
Medical and pharmaceutical companies sponsor The Royal Melbourne Hospital and its patients to participate in their clinical trials.
Our dementia researchers have been part of the global commercial trial TRAILBLAZER – established by Eli Lilly, the pharmaceutical company behind the drug Donanemab – for the treatment of Alzheimer’s Disease.
This week, Head of Asia Pacific Clinical Trials at Eli Lilly, Andrew Huxley, gives us a glimpse into the process – and success of this trial – as a Sponsor.
Eli Lilly and Company | The Royal Melbourne Hospital |